Q-omics provides the consensus-scored RIMS4 profile across patient tissues and cancer cell-line models. RIMS4 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RIMS4 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, RIMS4 RNA expression shows 16,144 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, COAD, and TGCT as cancer lineages where RIMS4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RIMS4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RIMS4 survival associations across molecular data types. RIMS4 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (9) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RIMS4 RNA expression–survival associations across cancer types. High RIMS4 expression shows unfavorable associations in KIRP, LUSC, BLCA and LIHC, but favorable associations in BRCA and ACC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RIMS4 RNA expression.
This table summarizes RIMS4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RIMS4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RIMS4 shows lower tumor expression in COAD, HNSC, THCA, KIRC, LUAD and STAD. The COAD box plot shows higher RIMS4 RNA expression in normal versus tumor tissue (log2 FC = −1.150, t-test p < 0.001).
This table shows molecular features associated with RIMS4 in patient tissues and cancer cell lines. In patient samples, RIMS4 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, RIMS4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BONE and SOFT_TISSUE.
